Free Trial

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Catalyst Pharmaceuticals logo
$21.64 +0.19 (+0.89%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$21.35 -0.29 (-1.34%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Key Stats

Today's Range
$21.12
$21.62
50-Day Range
$21.19
$26.31
52-Week Range
$14.97
$26.58
Volume
687,432 shs
Average Volume
1.12 million shs
Market Capitalization
$2.64 billion
P/E Ratio
13.78
Dividend Yield
N/A
Price Target
$32.83
Consensus Rating
Buy

Company Overview

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

CPRX MarketRank™: 

Catalyst Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 26th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Catalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Catalyst Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Catalyst Pharmaceuticals is 13.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Catalyst Pharmaceuticals is 13.78, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.

  • Price to Earnings Growth Ratio

    Catalyst Pharmaceuticals has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Catalyst Pharmaceuticals has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Catalyst Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.07% of the float of Catalyst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Catalyst Pharmaceuticals has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Catalyst Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Catalyst Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.07% of the float of Catalyst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Catalyst Pharmaceuticals has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Catalyst Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Catalyst Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    18 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,879,369.00 in company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Catalyst Pharmaceuticals' insider trading history.
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
CPRX Catalyst Pharmaceuticals, Inc. - Seeking Alpha
See More Headlines

CPRX Stock Analysis - Frequently Asked Questions

Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of 2025. Since then, CPRX shares have increased by 3.7% and is now trading at $21.64.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a net margin of 36.91% and a trailing twelve-month return on equity of 42.45%.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CPRX
Employees
80
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$32.83
High Stock Price Target
$36.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+51.7%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
13.78
Forward P/E Ratio
11.39
P/E Growth
0.87
Net Income
$163.89 million
Pretax Margin
48.34%

Debt

Sales & Book Value

Annual Sales
$491.73 million
Cash Flow
$2.47 per share
Price / Cash Flow
8.77
Book Value
$6.10 per share
Price / Book
3.55

Miscellaneous

Free Float
109,290,000
Market Cap
$2.64 billion
Optionable
Optionable
Beta
0.66

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CPRX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners